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Background: Despite recent malaria containment and control efforts leading to reduced incidence, Cambodia
remains endemic for both Plasmodium vivax and multidrug-resistant Plasmodium falciparum malaria. Little has been
reported in the peer-reviewed literature regarding the burden of severe malaria (SM) in Cambodia.
Methods: Medical records for all patients admitted to the Battambang Referral Hospital (BRH) with an admitting or
discharge diagnosis of SM from 2006 to 2009 (suspected SM cases) were reviewed. Those meeting the case
definition of SM according to retrospective chart review and investigator assessment of probable cases, based on
published national guidelines available at the time, were analysed for trends in demographics, mortality and
referral patterns.
Results: Of the 537 suspected SM cases at BRH during the study period, 393 (73%) met published WHO criteria for
SM infection. Despite limited diagnostic and treatment facilities, overall mortality was 14%, with 7% mortality in
children 14 and under, but 19% in adults (60% of cases). Cerebral malaria with coma was relatively rare (17%), but
mortality was disproportionately high at 35%. Mean time to hospital presentation was five days (range one to
30 days) after onset of symptoms. While patients with delays in presentation had worse outcomes, there was no
excess mortality based on treatment referral times, distance travelled or residence in artemisinin-resistance
containment (ARC) Zone 1 compared to Zone 2.
Conclusions: Despite limitations in diagnosis and treatment, and multiple confounding co-morbidities, mortality
rates at BRH were similar to reports from other countries in the region. Interventions to improve access to early
diagnosis and effective treatment, combined with modest improvements in intensive care, are likely to reduce
mortality further. Patients referred from Zone 1 did not have excess mortality compared to Zone 2 ARC areas.
A steep decrease in SM cases and deaths observed in the first half of 2009 has since continued, indicating some
success from containment efforts despite the emergence of artemisinin resistance in this area.* Correspondence: chanthapl@afrims.org
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By definition, patients with severe malaria are in critical
condition and require emergency therapy with paren-
teral drugs [1]. Untreated, mortality approaches 100%.
Little has been reported in the peer-reviewed litera-
ture about the burden of severe malaria in Western
Cambodia, located in World Health Organization’s
(WHO) Zone 1 artemisinin resistance containment
(ARC) area.
Through implementation of a successful national ma-
laria control programme, officially reported malaria in-
cidence in Cambodia decreased by more than 50%
between 2001–2010, from 11.03 cases per 1,000 in 2000
to 4.07 cases per 1,000 in 2010. Malaria mortality stea-
dily decreased over the last decade from 5.2 deaths
(in 2001) to 0.98 deaths per 100,000 in 2010 [2]. Despite
these successes, 60% of Cambodia's territory continues
to be endemic for malaria, though much of this is





















































* Represents the first 6 months 
Figure 1 Morbidity, mortality (number of deaths per 100,000 per yea
referral hospitals between 2006–9, Cambodia versus Battambang Refeastern provinces, with artemisinin resistance emerging
in the west.
In 2007 an estimated 2.13 million Cambodians (about
15% of the total population) living within 2 km of an en-
demic forested area were at risk of malaria, with 42,124
confirmed cases. There were 2,648 severe cases admitted
to referral hospitals, of which 219 died. Data from
the National Center for Parasitology, Entomology and
Malaria Control, Cambodia (CNM) in 2007 indicated
that Battambang Province had the second highest case-
fatality rate (CFR) nationally (17.4%) – double the na-
tional CFR (Figure 1).
Study objectives were to assess incidence of severe
malaria at a tertiary referral hospital, and further cha-
racterize the presentation of severe malaria in this
resource-limited setting based on WHO recommended
case definitions. A priori, it was suspected that access to
pre-hospital care, drug availability and compliance, and
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r) and case fatality rates (CFR, % deaths) from severe malaria in
erral Hospital.
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two separate ARC zones served by Battambang Referral
Hospital (BRH) were assessed. The operational utility of
published guidelines for the diagnosis and management
of severe malaria were also evaluated. The authors re-
port here the first data on the burden of severe mala-
ria at the government referral hospital in Battambang,
Cambodia’s second largest city, and the first area in
the world to report artemisinin-resistant malaria [3].
Methods
Study location
The study was conducted at the BRH, located in
Battambang City in Battambang Province, Western
Cambodia (Figure 2). BRH is a 270-bed facility and the
main hospital for Battambang city and surrounding dis-
tricts and admits on average 2,000 patients per month.
Identification of cases
Medical records for all patients admitted to the BRH
from January 2006 to June 2009 with an admission and/Figure 2 Map of Cambodia with study site location and case fatality r
showing a map of Battambang Province with case fatality rates accoror discharge diagnosis of severe malaria (irrespective of
confirmation by slide or rapid diagnostic test) were
reviewed to analyse morbidity, mortality, demography
and referral patterns. Since no separate log for severe
malaria cases existed, all hospital records for the study
period were searched in order to identify the severe mal-
aria cases. Individual patient records were reviewed by a
study physician, and data systematically extracted onto
case report forms. Discharge diagnoses were reviewed
independently for adherence to the Cambodian national
diagnosis and treatment guidelines in use at the time.
Severe malaria was defined as a complicated case of ma-
laria infection (Plasmodium falciparum and/or Plasmo-
dium vivax) presenting with one or more criteria of
severe disease [1]. WHO criteria for severe malaria were
adopted by the Ministry of Health as part of the
National Malaria Treatment Guidelines in Cambodia
and all clinicians would have had access to these guide-
lines at the time of the study. The availability of means
to assess the various diagnostic and prognostic parame-
ters is outlined in Table 1.ates according to province of residence/origin, with inset
ding to district of residence.
Table 1 Availability of means to assess diagnostic and prognostic parameters, and provide treatment of severe malaria
at Battambang Referral Hospital
WHO severe malaria
criteria
Description as published in national guidelines Availability
at BRH
Treatment available
Prostration Inability to sit upright without support or to drink Yes Supportive only
Impaired consciousness Modified Glasgow score ≤ 9 in adult and children >5 years
old or Blantyre coma score ≤ 2/5 in children who have not
learned to speak
Yes Supportive only
Respiratory distress Sustained nasal flaring, intercostals recession and deep
or fast breathing (RR >25/min in adults and >40/min
in children)
Yes Limited - no ventilators,
low flow oxygen only
Multiple convulsions > 1/24 h Yes Parenteral or NG diazepam
Circulatory collapse BP <50 mmHg before 5 years old or BP <80mmHg above
5 years old, cool peripheries, weak pulses
Yes Peripherally administered
IV pressors, fluids
Pulmonary oedema Radiological features Yes Limited - diuretics, oxygen,
morphine
Abnormal bleeding (No definition provided) Yes Blood transfusion (limited)
Jaundice (No definition provided) Yes Supportive
Haemoglobinuria (No definition provided) Yes Blood transfusion (limited)
Frequent vomiting Vomiting everything with inability to retain food or medicines Yes Antiemetic drugs, parenteral
route of drug administration
Laboratory finding
Severe anaemia (or pallor) Hb <5g/dl or Ht <15% Yes Blood transfusion (limited)
Hypoglycaemia Glycaemia <2.2 mmol/l or 0.4 g/l Yes IV dextrose
Metabolic acidosis Plasma bicarbonate <15 mmol/l No IV fluids
Hyperlactataemia Plasma lactate >5 mmol/l No IV fluids
Hyperparasitaemia P. falciparum “++++” or >200 000 parasites/μl Often Intramuscular artemether
Renal failure (or oliguria) Urine output <400 ml/24 h or plasma creatinine>265 μmol/l
in adult or urine output <12 ml/kg/24 h or plasma creatinine
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tive’ patients indicates those with a presence of asexual
malaria parasites as detected by microscopy or rapid
diagnostic test. Overall CFR and number of cases who
died included those dying in hospital, as well as those
who were discharged to home in worsening (moribund)
condition. The retrospective hospital record review
was carried out in compliance with the Declaration of
Helsinki 2000, following protocol approval by the
Walter Reed Army Institute of Research IRB and the Na-
tional Ethical Committee for Health Research (NECHR)
in Cambodia. Personal identifying information was not
collected on the case report forms.
Data analysis
Data were translated where needed from French and/or
Khmer into English, and transcribed from medical re-
cords onto paper case report forms, and analysed using
SPSS 12.0.0 for Windows. Double data entry was per-
formed using Microsoft Excel to minimize transcription
errors. Descriptive statistical analyses were performed for
demography, referral patterns, symptoms, signs, admittinglaboratory parameters, complications with respect to sur-
vival outcomes, and case management data. Fisher’s exact
test (two-sided) was used to compare proportions from
non-parametric tests when the expected values were less
than five. Mortality risk was expressed with odds ratios
(OR) and 95% confidence intervals (95% CI). Multiple lo-
gistic regression analysis was used to calculate adjusted
odds ratios (aOR) to evaluate associations of mortality
with presenting signs and symptoms, and complications
occurring during hospital admission. Variables with crude
OR significant at the level of p <0.2 in univariate analyses
were included in a multivariate analysis.Results
Between January 2006 and June 2009, a total of 537 re-
cords from suspected severe malaria cases were reviewed
from patients admitted or discharged from BRH with a
diagnosis of severe malaria. After review by study physi-
cians, 393 patients met published Cambodian severe ma-
laria case definitions and were considered to be ‘probable
severe malaria cases’ (Figure 3).
Figure 3 Study flow diagram.
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Overall CFR among the 393 probable severe malaria
cases was 14.0% (55 out of 393), with the majority dying
(38 or 9.7%) in hospital. The majority were male (224 or
57.0%), aged between five and 30 (median age 18 years),
and were school-aged children (107 or 27%) or farmers(101 or 26%). Most patients (92%) were self-referred,
arrived by private vehicle, and resided in Battambang
Province (Table 2). Among the 393 probable severe
malaria cases, 265 (67%) had malaria diagnoses confirmed
by blood smear or rapid diagnostic test (RDT). Malaria
species identified in the 265 smear/RDT confirmed cases
Table 2 Demographic and clinical characteristics of patients that met severe malaria criteria (n=393)
Slide positive Slide negative/Not done
Total Survived Died Total Survived Died
n n (%) n (%) n n (%) n (%)
Age category
0-4 30 28 (93) 2 (7) 23 18 (78) 5 (22)
5-14 72 70 (97) 2 (3) 41 36 (88) 5 (12)
15-30 89 70 (79) 19 (21) 27 24 (89) 3 (11)
31-49 53 44 (83) 9 (17) 26 22 (85) 4 (15)
>=50 21 17 (81) 4 (19) 11 9 (82) 2 (18)
Sex
Male 152 133 (88) 19 (13) 72 62 (86) 10 (14)
Female 113 96 (85) 17 (15) 56 47 (84) 9 (16)
Occupation
Labour 40 30 (75) 10 (25) 7 6 (86) 1 (14)
Government 3 2 (67) 1 (33) 2 2 (100) 0 (0)
Housewife 11 8 (73) 3 (27) 6 4 (67) 2 (33)
Farmer 66 52 (79) 14 (21) 35 30 (86) 5 (14)
Business 2 2 (100) 0 (0) 1 1 (100) 0 (0)
Monk 1 1 (100) 0 (0) 1 1 (100) 0 (0)
School-aged child 74 69 (93) 5 (7) 33 29 (88) 4 (12)
Unemployed 15 14 (93) 1 (7) 6 5 (83) 1 (17)
Other 48 46 (96) 2 (4) 36 30 (83) 6 (17)
Referral by
Self 173 152 (88) 21 (12) 79 72 (91) 7 (9)
Private sector 1 1 (100) 0 (0) 11 7 (64) 4 (36)
Government Referral Hospital 9 6 (67) 3 (33) 37 29 (78) 8 (22)
Government Health Centre 82 70 (85) 12 (15) 1 1 (100) 0 (0)
Arrived by
Private vehicle 181 157 (87) 24 (13) 76 69 (91) 7 (9)
Government ambulance 78 67 (86) 11 (14) 46 35 (76) 11 (24)
Parasite species
Pf 217 185 (85) 32 (15)
Pv 33 29 (88) 4 (12)
Mixed Pf+Pv 15 15 (100) 0 (0)
Negative 110 94 (85) 16 (15)
ND 18 15 (83) 3 (17)
Parasitaemia time 0
No or low (1+ to 3+) 145 122 (84) 23 (16) 110 94 (85) 16 (15)
Hyperparasitaemia 113 101 (89) 12 (11) 0 0 (0) 0 (0)
(4+ to 6+)
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and 15 documented mixed infections (5.7%) positive for
both P. falciparum and P. vivax (Table 2).
Out of 55 total deaths reported, there were 36 deaths
among the 265 smear-positives (mortality rate 13.6%),versus 19 deaths among the 128 smear-negatives (14.9%
mortality). Lowest case fatalities were found in the five
to 14 year age group (6.2%), while most fatalities were
15 to 30 years old (19%) or older than 50 (19%). The
under-five mortality rate was 13%. Occupations with the
Table 3 Signs and symptoms on admission in probable
severe malaria patients (n= 393)
Sign/
symptoms
Total Died OR (95% CI) p-value*
n (%) n (%)
Fever 372 (95) 50 (13) 0.5 (0.2, 1.4) 0.19
Headache 247 (63) 32 (13) 0.8 (0.4, 1.4) 0.46
Dark urine 220 (56) 24 (11) 0.6 (0.3, 1.0) 0.06
Chills 207 (53) 26 (13) 0.8 (0.4, 1.4) 0.47
Impaired 166 (42) 23 (14) 1.0 (0.6, 1.8) 1
consciousness
(excl coma)
Abdominal pain 133 (34) 15 (11) 0.7 (0.4, 1.3) 0.29
Vomiting 104 (26) 10 (10) 0.6 (0.3, 1.2) 0.14
Anorexia 77 (20) 6 (8) 0.5 (0.2, 1.1) 0.1
Fatigue 75 (19) 8 (11) 0.7 (0.3, 1.5) 0.46
Coma 65 (17) 23 (35) 5.0 (2.7, 9.4) 0
Dyspnea 59 (15) 14 (24) 2.2 (1.1, 4.4) 0.03
Pallor 50 (13) 19 (38) 5.2 (2.7, 10.2) 0
GI Bleeding 41 (10) 4 (10) 0.6 (0.2, 1.9) 0.63
Dizziness 35 (9) 4 (11) 0.8 (0.3, 2.3) 0.8
Bleeding 26 (7) 5 (19) 1.5 (0.5, 4.2) 0.39
Nausea 25 (6) 4 (16) 1.2 (0.4, 3.6) 0.77
Jaundice 24 (6) 4 (17) 1.2 (0.4, 3.8) 0.76
Sweating 24 (6) 6 (25) 2.2 (0.8, 5.8) 0.13
Convulsion 20 (5) 5 (25) 2.2 (0.8, 6.2) 0.18
Confusion 11 (3) 0 (0) - -
Neck stiffness 2 (1) 1 (50) 6.2 (0.4, 101) 0.26
*Fisher's Exact Test (2-sided).
Adjusted for Dark Urine, Coma, Dyspnea and Pallor and Age Group, aOR
(95% CI) of Dark Urine= 0.4 (0.2, 0.8), aOR of Coma = 5.8 (2.9, 11.5), aOR of
Dyspnea = 2.5 (1.2, 5.4), aOR of Pallor = 4.2 (1.9, 9.0) and aOR of Age >
15 = 2.0 (0.9, 4.1).
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kers (20%), farmers (19%), and housewives (29%). A
higher death rate was found in referred patients (19.2%),
in particular those referred from government health fa-
cilities, versus patients who came directly to the hospital
(8%). There were two fatalities among the 13 pregnant
severe malaria cases (both P. falciparum infections), as
well as one spontaneous abortion and three stillbirths
(all P. falciparum). The only pregnant P. vivax case
survived with normal delivery at term during hospital
admission.
Signs and symptoms on admission
The most common presenting signs and symptoms
among 393 probable severe malaria cases included fever
(95%), headache (63%), dark urine (56%), chills (53%),
and impaired consciousness (42%). There were 65 pa-
tients who presented in a coma (17%). The only pre-
senting symptoms, adjusted for age group (aOR age >15
years=2.0, 95% CI 0.9-4.1) that remained significantly as-
sociated with a fatal outcome after a multiple logistic re-
gression analysis were coma (aOR=5.8, 95% CI 2.9-11.5),
pallor (aOR=4.2, 95% CI 1.9-9.0), dyspnea (aOR= 2.5,
95% CI1.2, 5.4) and dark urine (aOR=0.4, 95% CI 0.2-0.8)
(Table 3).
Laboratory data
Laboratory assessment at BRH was limited and included
microscopy for parasitaemia (94%), white blood cell
count (92%), haematocrit (63%) or haemoglobin (6%),
platelets (48%) and plasma glucose (32%). Assessment of
liver enzymes (3%) were done infrequently, and other
commonly used tests including blood urea nitrogen, cre-
atinine, bilirubin, albumin, plasma lactate and bicarbon-
ate were unavailable. Higher parasitaemia based on the
qualitative scoring system used was not associated with
higher mortality. Although severe anaemia was common,
with approximately 29% of patients having haematocrit
values less than 15% at initial presentation, mean pre-
senting haematocrit values between non-survivors and
survivors were similar (25.2% versus 24.0%), and no pa-
tient had a presenting glucose level less than 40 mg/dL.
Non-survivors had higher mean leukocyte counts than
survivors (10.6 versus 8.0x 103 cells/ml, p-value =0.02).
Of 191 patients tested, the majority had a platelet count
greater than 150,000/μL, with the mean platelet count
significantly lower in non-survivors (183,000/μL versus
208,000/μL, p-value = 0.04) (Table 4).
Clinical course and complications
Features of the clinical course, and complications that
developed during hospital admission are shown in
Table 5 (all cases) and Table 6 (children <15 years old),
along with their association with mortality. In patientswho met the severe malaria case definition (all age
groups), the most common clinical features included pros-
tration (68%), impaired consciousness (65%), and respira-
tory distress (48%), and all three were associated with a
substantially increased risk of mortality in a univariate
analysis. Circulatory collapse (15%), renal failure (27%),
and pulmonary oedema (2%), though less common, were
also associated with increased mortality, while severe an-
aemia defined as a haematocrit of less than 15 (55%) and
hyperparasitaemia (33%) were not. In multivariate ana-
lysis, only circulatory collapse (aOR67.5; 95% CI 23.2-196)
and renal failure (aOR19.7; 95% CI 4.6-83.9) remained sta-
tistically significantly associated with a higher mortality
risk independent of age. Clinical features were similar in
the under 15 age group, although the majority (60%)
developed multiple convulsions during their hospital
stay. Circulatory collapse (adjusted OR= 186, 95% CI 30.4,
1,143) was the only complication significantly associated
Table 4 Laboratory values reported on admission in probable severe malaria patients (n= 393)
Laboratory test Total evaluated Mean (S.D) Reference range
n (%) Range Died Survived p-value* Category n
WBC (× 103cells/ml) 368 (94) 1.6-35.2 10.6 ± 7.3 8.0 ± 4.8 0.02 ≤ 12 303
> 12 65
Hematocrit (%) 253 (64) 5.0-50 25.2 ± 10.4 24.0 ± 10.4 0.5 ≤ 15 74
16 to 30 109
≥ 31 70
Hemoglobin (g/dl) 22 (6) 3.0-16.2 9.8 ± 2.6 9.1 ± 4.2 0.8 < 10 12
≥ 10 10
Platelets (× 103cells/ml) 191 (49) 10-450 183 ± 49.4 208 ± 47.4 0.04 ≤ 100 2
101-149 11
≥ 150 178




SGOT (IU/L) 11 (3) 19-390 144 ± 154.5 123 ± 126 0.8 < 3 times ULN 6
≥ 3 times ULN 5
SGPT (IU/L) 11 (3) 20-430 66±45 110 ± 137 0.6 < 3 times ULN 7
≥ 3 times ULN 4
Total evaluated Reference range
n (%) Range # (%) Died # (%) Survived p-value** Category n
Parasitaemia 368 (94) 0 to +6 16 (15) 94 (85) 0.4 Negative 110
23 (16) 122 (84) 1-3+ 145
12 (11) 101 (89) ≥ 4+ 113
p< 0.05, *t-test (2-sided) or **One-Way ANOVA.
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in the younger age group.
Treatment
Nearly 90% (345) of suspected severe malaria cases re-
ceived parenteral therapy on admission which included
either an anti-malarial drug alone (238 or 61%), or a
combination of anti-malarial and an antibiotic (107 or
27%) (Table 7). Intramuscular artemether was the most
frequently administered anti-malarial, given to 324 or
82% of suspected severe malaria patients on admission.
Aminopenicillins, ciprofloxacin and cephalosporins were
the most frequently given antibiotics.
Treatment delay, cost and residence according to ARC Zone
Mean time to hospital presentation in severe malaria pa-
tients was five days (range one to 30 days) after onset of
symptoms. No clear relationship was observed between
treatment delay and outcome. Overall CFR of patients
originating from ARC Zone 1 districts was lower than
those from Zone 2 districts (11% versus 15%) (Table 8).
For the majority (45%) of the study population,treatment was subsidized by local NGOs with a fixed US
$20 payment, while 38% (150/393) paid for treatment
out-of-pocket at a cost of between US$2.5 and 75
(median US$12.5). For 67 patients or 17%, no cost data
were available, meaning these patients did not pay or no
payment records could be found.
Discussion
This is one of the few studies to describe the presen-
tation and epidemiology of severe malaria in Western
Cambodia, a low transmission setting with multidrug-
resistant P. falciparum, and an increasing predominance
of P. vivax malaria. The study provides baseline informa-
tion on the burden of severe malaria in a referral hos-
pital near the epicentre of global anti-malarial drug
resistance (WHO Zone 1) during the 2.5 years preceding
the Artemisinin Resistance Containment Project and
supports other preliminary evaluations reporting success
in containment and reduction of mortality rates [4].
These intense efforts led by WHO and others provided
bed net distribution, and trained local village malaria
workers to provide earlier case detection and treatment
Table 5 Clinical course and complications experienced during hospital admission in probable severe malaria patients
(n=393)
Neg Pf Pv Pf+Pv Not recorded Total Died OR (95% CI) p-value*
n n (%) n (%)
Prostration 82 150 16 5 12 265 (68) 53 (20) 15.6 (3.7, 65.2) 0
Impaired consciousness 81 143 14 5 11 254 (65) 53 (21) 18.1 (4.3, 75.4) 0
Respiratory distress 55 105 12 5 9 186 (48) 39 (21) 3.9 (2.0, 7.5) 0
Severe anaemia 55 90 11 3 10 169 (55) 27 (16) 1.1 (0.6, 2.1) 0.75
Hyperparasitaemia 1 101 7 11 8 128 (33) 13 (10) 0.6 (0.3, 1.1) 0.12
Jaundice 21 38 4 1 4 68 (17) 14 (21) 1.7 (0.9, 3.5) 0.12
Abdominal bleeding 23 29 5 0 5 62 (16) 12 (19) 1.6 (0.8, 3.2) 0.23
Frequent vomiting 17 34 6 3 1 61 (16) 5 (8) 0.5 (0.2, 1.3) 0.23
Circulatory collapse 17 32 7 1 3 60 (15) 43 (72) 67.5 (30.2, 150.8) 0**
Renal failure 8 16 2 0 1 27 (7) 16 (59) 16.8 (7.1, 39.7) 0**
Multiple convulsion 7 11 2 2 2 24 (6) 7 (29) 2.8 (1.1, 7.1) 0.03
Macroscopic 6 6 0 0 0 12 (3) 3 (25) 2.5 (0.7, 9.7) 0.17
haemoglobinuria
Hypoglycemia 1 7 0 2 0 10 (7) 3 (30) 1.5 (3.6, 6.2) 0.7
Pulmonary oedema 2 2 1 0 0 5 (2) 4 (80) 42.3 (4.5, 398) 0
*Fisher's Exact Test (2-sided).
**Adjusted for age group, circulatory collapse and renal failure, aOR (95% CI) of circulatory collapse=67.5 (23.2, 196) and aOR of renal failure=19.7 (4.6, 83.9).
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cases [5,6]. Following the downward trend in other Con-
tainment Project provinces, severe malaria incidence and
CFR in Battambang Province reported to the National
Malaria Control Program continued to decline signifi-
cantly after 2009 with only two deaths out of 116 severe
cases in 2010 and one death out of 101 severe cases inTable 6 Clinical course and complications experienced during
for only those aged 0 to 15 years (n=130)
Neg Pf Pv Pf+Pv Not re
n
Prostration 51 65 8 2
Impaired consciousness 51 65 8 2
Multiple convulsion 3 83 12 1
Severe anaemia 36 51 5 2
Respiratory distress 26 34 4 3
Hyperparasitaemia 1 33 1 5
Frequent vomiting 14 17 3 2
Abdominal bleeding 12 9 0 0
Circulatory collapse 8 3 1 7
Jaundice 6 4 0 0
Macroscopic haemoglobinuria 3 0 0 0
Pulmonary oedema 0 0 1 0
Renal failure 0 0 0 0
Hypoglycaemia 0 0 0 0
*Fisher's Exact Test (2-sided).
**Adjusted for Circulatory Collapse, aOR (95% CI) of Circulatory Collapse = crude OR2011 [7]. Other likely contributors to the reduction in
severe disease in the interim have included malaria case
management training, a ban on artemisinin monother-
apy, a government crack-down on counterfeit drugs and
illegal pharmacies, improved supply of good quality anti-
malarials, an increased programme focus on migrant
and mobile populations (including the military), andhospital admission in probable severe malaria patients
corded Total Died OR (95% CI) p-value*
n (%) n (%)
4 130 (78) 13 (10) 3.8 (0.5, 29.9) 0.31
4 130 (78) 13 (10) 3.9 (0.5, 30.8) 0.31
1 100 (60) 1 (1) 2.9 (0.3, 27.4) 0.36
3 97 (58) 10 (10) 1.4 (0.4, 4.8) 0.77
3 70 (42) 11 (16) 8.7 (1.9, 40.5) 0
1 41 (25) 1 (2) 0.2 (0.03, 1.6) 0.12
1 37 (22) 1 (3) 0.2 (0.03, 2.0) 0.2
0 21 (13) 3 (14) 2.0 (0.5, 7.7) 0.4
0 19 (11) 10 (53) 186 (30.4, 1143) 0**
0 10 (6) 2 (20) 3.0 (0.6, 15.8) 0.2
0 3 (2) 1 (33) 5.7 (0.5, 66.6) 0.24
0 1 (1) 0 (0) 1.0 (1.0, 1.1) 1
0 0 (0) 0 (0) - -
0 0 (0) 0 (0) - -
= 186 (30.4, 1143).
Table 7 Anti malarial and antibiotic treatment on





n (%) n (%)
Only anti malarials 238 (61) 25 (11)
Only antibiotics 18 (5) 2 (11)
Antibiotics and anti malarials 107 (27) 22 (21)
No anti-malarials or antibiotics 30 (8) 6 (20)
Number and type of anti malarials
At least one anti-malarial 345 (88) 47 (14)
Two or more anti-malarials 15 (4) 2 (13)
Artemether 324 (82) 44 (14)
Artesunate + Mefloquine 13 (3) 0 (0)
Chloroquine 10 (3) 1 (10)
Quinine 9 (2) 3 (33)
Mefloquine 4 (1) 1 (25)
DHA+Piperaquine 2 (1) 0 (0)
DHA 2 (1) 1 (50)
Number and type of antibiotics
At least one antibiotic 125 (32) 24 (19)
Two or more antibiotics 15 (4) 4 (27)
Aminopenicillins 61 (16) 10 (16)
Cephalosporins 37 (9) 14 (38)
Ciprofloxacin 27 (7) 0 (0)
Gentamycin 10 (3) 4 (40)
Co-trimoxazole 4 (1) 0 (0)
Metronidazole 4 (1) 0 (0)
Tetracycline 1 (0) 0 (0)
Lon et al. Malaria Journal 2013, 12:217 Page 10 of 13
http://www.malariajournal.com/content/12/1/217basic improvements in infrastructure such as road access
in Western Cambodia. The relationship between level
of artemisinin tolerance and pathogenicity of malaria
parasites is unclear. High levels of differentiation in
artemisinin-resistant P. falciparum subpopulations have
recently been demonstrated in Cambodia [8] and future
research may or may not link these to different levels in
pathogenicity.
On review of the hospital records, it was often appa-
rent that malaria was a co-existing infection of another
serious condition, such as meningitis, sepsis and gastro-
intestinal haemorrhage which is not unexpected, given
the recent evidence of falciparum malaria infection as a
risk factor for bacteraemia in African children [9]. Bac-
terial cultures that could have ruled out bacteraemia,
were not available at BRH for this population.
Despite substantial limitations, diagnostic and treat-
ment guidelines were reasonably well adhered to where
possible at this facility, likely contributing to an overall
CFR of 14.2% which was intermediate compared toother reports from the region. CFR in other retros-
pective studies in the region have varied from 1.8% in
Thailand [10], 6.3% in the Philippines [11], to 35% in
Malaysia [12]. This compares to recent mortality rates
in African studies, largely in children, ranging from 4.5%
in Cameroon [13] to 11.5% in Madagascar [14] to up to
22% in children with bacteraemia in Mozambique [6,15].
Despite the emergence of artemisinin resistance in
Western Cambodia during the study period, cases of se-
vere malaria and deaths declined in BRH and nationally.
Overall CFR was lower in severe malaria patients resid-
ing in districts with confirmed artemisinin resistance
(Zone 1), likely resulting from increased active case de-
tection and early treatment. Overall malaria incidence in
Cambodia increased from 4.1 per 1,000 in 2008 to 6.22
per 1,000 in 2009 attributed to increased migrational
movements, while CFR of severe malaria cases contin-
ued to decline [2].
Although life-threatening malaria complications can
affect patients of all ages, disease presentation and mor-
tality have been found to be closely related to trans-
mission intensity and age of the patient [16]. In a low
transmission setting such as this, where immunity may
never be acquired, older patients may have higher mor-
tality rates owing to delayed presentation. The most
frequent complications associated with mortality, par-
ticularly in older patients, were prostration, respiratory
distress and coma, with 35% of comatose patients dying
on or soon after admission. Coma and metabolic aci-
dosis have been found to be the most significant risk
factors for death in both children and adults in prior
studies in Asia [17,18]. Others have demonstrated that
renal function monitoring in these patients may be cru-
cial for survival [16,19]. The lack of metabolic and
chemistry testing inhibited the ability to identify meta-
bolic acidosis and renal dysfunction early, making prog-
nosis and management more challenging. Of the limited
diagnostic testing available, mortality did appear to cor-
respond with laboratory abnormalities for both leukocyte
and platelet counts, lending some limited prognostic
value to these tests. Elevated or depressed leukocyte
counts often indicate concomitant bacterial infections,
and patients may benefit from empiric antibiotic treat-
ment [20]. Thrombocytopaenia, one of the most common
laboratory abnormalities in severe malaria [21] also had
some prognostic value for severe disease though it did not
predict bleeding complications.
In addition to diagnostic and prognostic limitations,
challenges in management included lack of mechanical
ventilation units, renal haemodialysis, centrally adminis-
tered pressors, exchange transfusion capabilities or real
time haemodynamic and metabolic data to guide resus-
citation. Limited peritoneal dialysis was available at
times, but rarely employed. As a result, renal failure and
Table 8 Case fatality rates and treatment delay versus origin stratified according to artemisinin-resistance containment
(ARC) zone for probable severe malaria cases (n=393)
Province District Onset to presentation (days)
Total Died Survived Total
n n (%) n (%) n Mean SEM
Battambang 122 Samlot 11 (10) 101 (90) 112 5.1 0.3
Phnom Preuk 0 (0) 5 (100) 5 6.0 0.6
Kam Reang 1 (25) 3 (75) 4 5.5 3.2
Sampov Loun 0 (0) 1 (100) 1 3.0 -
Pailin 16 Pailin/Sala 3 (19) 13 (81) 16 6.7 1.8
Kroa
Pursat 2 Veal Veaeng 1 (50) 1 (50) 2 5.0 2.0
Total ARC Zone 1 140 16 (11) 124 (89) 5.3 0.3
Province District Onset to presentation (days)
Total Died Survived Total
n n (%) n (%) n Mean SEM
Battambang 241 Ratanak 10 (15) 55 (85) 65 6.0 0.7
Mondol
Banan 8 (18) 37 (82) 45 6.2 0.6
Battambang 4 (11) 32 (89) 36 5.4 0.6
Thmar Koul 3 (13) 21 (88) 24 5.2 0.4
Sangker 5 (24) 16 (76) 21 4.6 0.4
Moung Russey 3 (17) 15 (83) 18 7.8 1.6
Ek Phnom 1 (6) 17 (94) 18 5.1 0.6
Bavel 3 (43) 4 (57) 7 6.7 1.0
Koh Kralor 1 (14) 6 (86) 7 5.3 1.2
Other 12* 1 (8) 11 (92) 6.7 1.8
Total ARC Zone 2 253 39 (15) 214 (85) 5.8 0.3
*Banteay Meanchey(4), Pursat(4), Siem Reap(1), Sihanoukville(1), Svay Rieng(1), Takeo(1).
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in only 7% and 2% patients),were associated with the
highest CFR in this group.
Recent descriptions of treatment-seeking behaviour, cul-
tural practices and socio-economic barriers have revealed
causes for delays in appropriate malaria treatment in
Cambodia, representing an important potential area for
intervention to reduce mortality [22]. Several factors appear
to have contributed to mortality from severe malaria at the
BRH including delayed presentation, delayed admission re-
ferral, cultural beliefs, and difficulty accessing health care
facilities in this austere setting. The average time between
onset of symptoms and admission to BRH was 5.5 days,
greater in some of the outlying districts. Although
Cambodia has an extensive peripheral health centre net-
work, lack of public sector resources may prompt patients
to seek initial treatment directly at the highest level of care
possible, bypassing outlying networks. The majority of se-
vere cases (70%) presented directly to the BRH, and were
admitted directly for treatment to the intensive care unit,with only the minority (approximately 30%) being referred
from outlying centres. Referred patients (especially from
the public sector) had worse outcomes, suggesting in-
creased treatment delay and lack of pre-referral treatment
such as parenteral artemisinins, suppositories and/or
transfusion capability.
Roughly 90% of all patients discharged with a severe mal-
aria diagnosis at BRH received intramuscular artemether
on the day of admission, which at the time of publication
remains the current national standard of care for severe
malaria in Cambodia. A five to seven-day course is used,
followed by treatment with mefloquine, but is sometimes
unavailable, prompting patients to obtain drugs from
private-sector pharmacies risking counterfeit or substand-
ard treatment. Parenteral artesunate was not available in
Cambodia during the study period. Parenteral artesunate
currently remains the most effective treatment remaining
for severe malaria [23], and was found to be more effective
and less expensive than quinine in children in sub-Saharan
Africa [24] and adults in Southeast Asia [25]. Though
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artesunate suggest some degree of inferiority for intramus-
cular artemether [26], both were found to be effective, and
the relative simplicity of rapid intramuscular administration
in critical illness may support its continued use in
Cambodia. Availability and frequent of use of this life-
saving drug may explain the relatively low overall mortality
rates seen, particularly considering the limited array of diag-
nostic and treatment facilities available. Quinine continues
to be the first-line agent for pregnant women in Cambodia.
There has been recent recognition of the substantial
proportion of severe malaria cases attributable to P.
vivax in tropical regions [27]. Observed rates of severe
P. vivax in Southeast Asia and the Pacific have been high
in several reports, accounting for up to 25% of severe
malaria cases. While some have shown reduced risk of
severe disease attributable to P. vivax and/or mixed in-
fection in low transmission settings [28], others have
shown risks of severe disease to be increased, particu-
larly in young children and in areas with high grade
chloroquine resistance, though the latter has not been
reported in Cambodia [29]. Though P. vivax is typically
thought of as a relatively benign disease, 14.5% of pa-
tients meeting the case definition of severe malaria at
BRH during the study period had slide proven P. vivax,
and there were four documented deaths. There were no
deaths reported among 17 patients with documented
mixed infection. HIV-1 infection has been reported to
be an important risk factor for severe malaria and death
[30], but there was only one confirmed case of HIV co-
infection in this study population.
The study’s retrospective design placed limits on accur-
ately interpreting the underlying disease burden. Accurately
defining the terms ‘impaired consciousness’ and ‘prostra-
tion/coma’ retrospectively were challenging. WHO defines
impaired consciousness as a ‘rousable mental condition’,
and prostration as the inability to sit upright without sup-
port or drink. However, varying terms were used by clini-
cians at BRH, including descriptions such as “somnolence”,
“obnubilation”, “agitation”, “delirium”, “irritation”, “pre-
coma”, and in some cases a Glasgow Coma Score (GCS)
was given. In the retrospective analysis, the study team
adopted the term ‘coma’ for those found to have either a
clearly documented coma state, or understood to have an
unarousable coma based on GCS scores. Limitations on
diagnostic capabilities at this facility leaves open the
possibility that cases and/or complications may have
been missed. The study does not reflect cases that never
made it to medical attention, died out of hospital, or
were treated at local facilities, in the private sector
or at home. As such, the in-patient data are only repre-
sentative of the referral centre and not of the overall se-
vere malaria burden for this region of Cambodia.
Likewise, the non-availability of important diagnosticmeasurements may have resulted in under-reporting of
complications.
A large proportion of patients were slide-negative on ad-
mission, though nearly 50% of these patients still responded
to anti-malarials alone. In such cases, preliminary micro-
scopic diagnosis in hospital may have been obscured or
simply not performed due to pre-treatment out of hospital
prior to transfer. Many cases were diagnosed by rapid diag-
nostic kits or simply treated on clinical grounds. Patients
with negative malaria smears in this cohort had higher
crude mortality rates at 16% versus 11% in the patients with
high parasitaemia, possibly due to delays in diagnosis and
appropriate treatment, or earlier parenteral therapy in the
higher parasitaemia patients. In this setting, a high index of
suspicion for severe malaria remains warranted and may
prove lifesaving. However, an empiric treatment approach
to severe malaria should not preclude investigation of co-
morbidities, which were common.
Conclusions
BRH continued to have a significant number of severe
malaria cases between 2006–2009, suggesting that in-
terventions to improve access to early diagnosis and
treatment of malaria remain priorities for this region.
Diagnostic ambiguities were common in this setting,
with multiple confounding co-morbidities and limited
patient management resources. The key to preventing
mortality remains early detection, treatment and referral
where necessary, and maintaining a high index of suspi-
cion for severe malaria cases is essential. This includes
not only adherence to guidelines, but consideration of
the individual patients’ risks based on local endemicity,
clinical history, pre-hospital care, and severity of present-
ing illness syndromes. Co-administration of broad-
spectrum antibiotics in this resource-poor setting with
frequent co-infection and septicaemia may improve out-
come. A subset of technologically appropriate core
guidelines for diagnosis and management of severe mal-
aria may be useful in this setting, and monitoring of the
patient’s renal and acid–base balance through simple
chemistry panels may be a useful and cost-effective ad-
dition to management at this and similar facilities. The
drop in both numbers of severe cases and mortality dur-
ing the period immediately following this study suggests
some improvement in malaria control, likely to due to
large-scale containment efforts in the region.
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